Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$25.80 USD
+1.67 (6.92%)
Updated May 1, 2024 04:00 PM ET
After-Market: $25.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RNA 25.80 +1.67(6.92%)
Will RNA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
Other News for RNA
Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by Xtalks
Artisan International Small-Mid Fund Q1 2024 Earnings Preview
Interesting RNA Put And Call Options For December 20th
Edgewise gets EU orphan drug status for muscular dystrophy drug
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)